Gapping up
In reaction to strong earnings/guidance:
- WW +15%, MELI +12.8%, OLED +12.7%, ZIXI +9.5%, UCTT +9.1%, MNST +8.2%, CRC +7.6%, SHAK +6.5%, FNKO +6.2%, CBLK +6.1%, MTZ +6%, RMD +5.9%, PVG +5.8% (ticking higher; also Executive Chairman and founding shareholder, Robert Quartermain, will be retiring), DATA +5.2%, X +4.9%, XRAY +4.9%, BTE +4.3%, BLDR +4.2%, CUB +4%, LPLA +3.9%, VRAY +3.4%, NSA +3.1%, MSI +2.9%, BRKR +2.9%, NWL +2.9%, AMKR +2.7%, GSHD +2.7%, VST +2.7%, MPWR +2.5%, RUTH +2.4%, HTGC +2.2% (increases quarterly distribution to $0.32/share from $0.31/share and announces supplemental cash distribution of $0.01/share for the first quarter of 2019), G +2.2%, HSBC +2.2%, RPD +2.1%, CARB +2%, FSLR +1.9%, FCAU +1.7%, ERII +1.6%, PODD +1.1%, BIP +1%
Other news:
- BYND +9.1% (continued momentum)
- OBSV +2.4% (reports follow-up results from Phase 2b EDELWEISS clinical trial of linzagolix for the treatment of endometriosis-associated pelvic pain)
- AMZN +2.4% (Warren Buffett says Berkshire (BRK.B) has been purchasing shares of AMZN, according to CNBC)
- CHRS +2.3% (Coherus BioSciences and Amgen settle trade secrets action)
- DBD +1.5% (Director Anton bought 25K shares worth ~$225K, SVP of Services disclosed the purchase of ~20K shares worth ~$180K)
- TSLA +1.4% (boosts offering of common stock to 3.09 mln shares (at $243.00/share), says Musk may purchase up to $25 mln of the offering, boosts offering of 2.00% convertible senior notes due 2024 to $1.60 bln)
- ZLAB +1% (prices offering of 7,843,138 ADS's of $25.50 per ADS)
- AZN +0.8% (Qternmet XR approved in the US for the treatment of type-2 diabetes)
Analyst comments:
- MGNX +6.7% (upgraded to Outperform from Neutral at Wedbush)
- ICPT +2.1% (upgraded to Outperform from Market Perform at Wells Fargo)
- BMY +1% (upgraded to Overweight from Equal Weight at Barclays)